The control of hypertension should be 24 hours to reduce the risk of complications.

-experts analysed the different treatment options for high blood pressure in the 1980s Debate ” organized by Boehringer Ingelheim at the 17th National meeting of the SEH-LELHA

-Telmisartan helps reduce blood pressure in a uniform way throughout the perdosage of 24 hours íodo and prevent the occurrence of events and mortality in patients with high cardiovascular risk 1, 2, 3

Madrid, March 2012.- high blood pressure affects 26.4 per cent of the world’s adult population and is the first risk factor for cardiovascular disease; it is responsible for more deaths than any other pathologyincluding high cholesterol, diabetes or smoking.

The choice of the most appropriate treatment for hypertension depends on not only the figures of blood pressure, but the presence of other conditions, as risk factors or target organ injuries.

Therefore, Boehringer Ingelheim has organized, within the framework of the 17th National meeting which Spanish society of hypertension – Spanish League for the fight against Arterial hypertension (SEH-LELHA) held in Madrid from 7 to 9 March 2012, Debate 80 ” on choice of treatment in Arterial hypertension.

The debate has had as a novelty take place under an innovative format, in which the participants were clear and concise recommendations 80 seconds on treatment and on how, when and with what mechanisms start the same.

One of the main points discussed in this quotation is the importance of the control of hypertension during 24 hours. The doctor Alejandro de la Sierra, Chief of service of internal medicine of the Hospital Universitario Mutua Terrassa, explains that the risk of high pressure depends on the continuous load; Thus, their reduction should be uniform throughout the period which is between two shots of the drug, currently 24 hours ”. In addition, says the expert, it is proven that elements of high variability of blood pressure – as fluctuations throughout the day and the elevation that happens in the morning and usually superimposed at the end of the effective period of a dose prior to the administration of the followingthey are important in determining the risk of the patient.

In that regard, telmisartan (Micardis ®, Micardis Plus ® and Twynsta ®), Boehringer Ingelheim research, according to the expert, is one of the few drugs that has demonstrated its ability to prevent the occurrence of events and reduce mortality in patients of high cardiovascular risk, such as diabetics or those who have had a previous cardiovascular event ”. The benefits of 24-hour control are linked, according to the doctor de la Sierra, to its ability to reduce the pressure uniformly over the entire period of dosing.

This medication reduces and maintains the goal of blood pressure during 24 hours in a wide variety of patients with mild, moderate and severe hypertension.

The risk of a hypertensive patient with blood pressure figures controlled 24 hours of suffering a cardiovascular event could be the same as that of a person with normal tension that does not require treatment. Although this has not been specifically tested and, in general, believed that the risk of hypertensive in treatment remains higher than the Normotensive, the expert points out that, in fact this is due to the majority not get the proper control of the pressure and the presence of other equally important risk factors are more common in the poblacihypertensive ón ”.

The presence of other risk factors such as obesity, metabolic syndrome and diabetes increases the resistance to treatment becomes necessary, according to the doctor de la Sierra, one therapeutic greater effort in these patients to overcome such resistance, given that it is precisely these groups have higher cardiovascular risk ”.

Boehringer Ingelheim provide value through innovation ”

The Boehringer Ingelheim group is one of 20 of the world’s largest pharmaceutical companies. Headquartered in Ingelheim, Germany, works globally with 145 affiliated and has more than 42,000 employees. Since its foundation in 1885, the family-owned company is committed to the research, development, production and marketing of new products of high therapeutic value for human medicine and animal.

A central element of corporate culture of Boehringer Ingelheim is committed to socially responsible actions. For this reason, the company participates in social projects and take care of their partners, girls and families, offering everyone equal opportunities. Respect, equality of opportunity and the reconciliation of working life and the family constitute the basis of mutual cooperation. As well as the protection of the environment and sustainability that are always present in any activity of Boehringer Ingelheim.

Boehringer Ingelheim settled in Spain in 1952, and during these more than 50 years has evolved to be ranked No. 10 in the pharmaceutical sector in our country. The company is headquartered in Spain in Sant Cugat del Vallès (Barcelona), and currently has about 1,700 employees and two international production centres in Sant Cugat del Vallès and Malgrat de Mar.

referencia:

1. Technical sheet Twynsta 80/5 and 80/10.

2 Magic G. et to the. The 2007 Guide for the management of arterial hypertension. Journal of Hypertension 2007, 25: 1105 – 1187.

3. Micardis tab technical.